{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:23:54Z","timestamp":1792178634137,"version":"4.4.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bmcl.2025.130312","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T20:02:52Z","timestamp":1750276972000},"page":"130312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitors"],"prefix":"10.1016","volume":"128","author":[{"given":"Brandon D.","family":"Lowe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jcb.20179","article-title":"Regulation of histone deacetylase activities","volume":"93","author":"Sengupta","year":"2004","journal-title":"J Cell Biochem"},{"issue":"1\u20132","key":"10.1016\/j.bmcl.2025.130312_bb0010","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1615\/CritRevOncog.2015012997","article-title":"Histone deacetylases and mechanisms of regulation of gene expression","volume":"20","author":"Chen","year":"2015","journal-title":"Critical Rev TM Oncogenesis"},{"key":"10.1016\/j.bmcl.2025.130312_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.560487","article-title":"Small molecules targeting HATs, HDACs, and BRDs in cancer therapy","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130312_bb0025","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/S1097-2765(01)00414-2","article-title":"Acetylation of p53 activates transcription through recruitment of coactivators\/histone acetyltransferases","volume":"8","author":"Barlev","year":"2001","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer","volume":"15","author":"Muller","year":"2012","journal-title":"Nat Cell Biol"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130312_bb0035","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"De Ruijter","year":"2003","journal-title":"Biochem J"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4068\/cmj.2016.52.1.1","article-title":"HDAC and HDAC inhibitor: from cancer to cardiovascular diseases","volume":"52","author":"Yoon","year":"2016","journal-title":"Chonnam Med J"},{"key":"10.1016\/j.bmcl.2025.130312_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: a review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110607","article-title":"HDAC11: a rising star in epigenetics","volume":"131","author":"Liu","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.bmcl.2025.130312_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/TOG.S483","article-title":"Transcription regulation by class III histone deacetylases (HDACs)—Sirtuins","volume":"1","author":"Dai","year":"2008","journal-title":"Translational Oncogenomics"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130312_bb0060","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.canlet.2008.10.047","article-title":"HDAC expression and clinical prognosis in human malignancies","volume":"280","author":"Weichert","year":"2008","journal-title":"Cancer Lett"},{"issue":"16","key":"10.1016\/j.bmcl.2025.130312_bb0065","doi-asserted-by":"crossref","first-page":"13512","DOI":"10.1021\/acs.jmedchem.4c00541","article-title":"Hydrazides as inhibitors of histone deacetylases","volume":"67","author":"Carreiras","year":"2024","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/nrg2485","article-title":"The many roles of histone deacetylases in development and physiology: implications for disease and therapy","volume":"10","author":"Haberland","year":"2008","journal-title":"Nat Rev Genet"},{"issue":"26","key":"10.1016\/j.bmcl.2025.130312_bb0075","doi-asserted-by":"crossref","first-page":"4956","DOI":"10.1038\/s41388-020-1337-x","article-title":"HDAC8 promotes the dissemination of breast cancer cells via AKT\/GSK-3\u03b2\/snail signals","volume":"39","author":"An","year":"2020","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130312_bb0080","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3390\/ijms20092241","article-title":"Immunoepigenetics combination therapies: An overview of the role of HDACs in cancer immunotherapy","volume":"20","author":"Banik","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0085","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-08-0684","article-title":"Histone deacetylase 8 in neuroblastoma tumorigenesis","volume":"15","author":"Oehme","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130312_bb0090","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.24","article-title":"Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation","volume":"6","author":"Rettig","year":"2015","journal-title":"Cell Death Dis"},{"issue":"7415","key":"10.1016\/j.bmcl.2025.130312_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature11316","article-title":"HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle","volume":"489","author":"Deardorff","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130312_bb0100","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1021\/acs.jmedchem.5b01478","article-title":"Structure-based design and synthesis of novel inhibitors targeting HDAC8 from Schistosoma mansoni for the treatment of schistosomiasis","volume":"59","author":"Heimburg","year":"2016","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130312_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003645","article-title":"Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni","volume":"9","author":"Marek","year":"2013","journal-title":"PLoS Pathog"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0110","doi-asserted-by":"crossref","DOI":"10.1186\/s40885-019-0118-8","article-title":"Selective inhibition of histone deacetylase 8 improves vascular hypertrophy, relaxation, and inflammation in angiotensin II hypertensive mice","volume":"25","author":"Kee","year":"2019","journal-title":"Clin Hypertension"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130312_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002316","article-title":"Histone deacetylase 8 is required for centrosome cohesion and influenza a virus entry","volume":"7","author":"Yamauchi","year":"2011","journal-title":"PLoS Pathog"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130312_bb0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1021\/acsptsci.1c00243","article-title":"Validation of HDAC8 inhibitors as drug discovery starting points to treat acute kidney injury","volume":"5","author":"Long","year":"2022","journal-title":"ACS Pharmacol & Trans Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0125","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1080\/14756366.2017.1417274","article-title":"Zinc binding groups for histone deacetylase inhibitors","volume":"33","author":"Zhang","year":"2018","journal-title":"J Enzyme Inhibition Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130312_bb0130","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1039\/b703830p","article-title":"Isoform-selective histone deacetylase inhibitors","volume":"37","author":"Bieliauskas","year":"2008","journal-title":"Chem Soc Rev"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130312_bb0135","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/cmdc.202000934","article-title":"Strategies to design selective histone deacetylase inhibitors","volume":"16","author":"Melesina","year":"2021","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.bmcl.2025.130312_bb0140","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/1535-7163.MCT-07-2026","article-title":"MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo","volume":"7","author":"Fournel","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"7\u20138","key":"10.1016\/j.bmcl.2025.130312_bb0145","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.biocel.2007.02.009","article-title":"MS-275, a potent orally available inhibitor of histone deacetylases\u2014the development of an anticancer agent","volume":"39","author":"Hess-Stumpp","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.bmcl.2025.130312_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122615","article-title":"Oncology\u2019s trial and error: analysis of the FDA withdrawn accelerated approvals","volume":"346","author":"Preziosi","year":"2024","journal-title":"Life Sci"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130312_bb0155","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/ja.2011.35","article-title":"Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma","volume":"64","author":"VanderMolen","year":"2011","journal-title":"J Antibiotics"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130312_bb0160","doi-asserted-by":"crossref","first-page":"4747","DOI":"10.3390\/ijms21134747","article-title":"In vitro assessment of the genotoxic hazard of novel hydroxamic acid- and Benzamide-type histone deacetylase inhibitors (HDACI)","volume":"21","author":"Friedrich","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"24","key":"10.1016\/j.bmcl.2025.130312_bb0165","doi-asserted-by":"crossref","first-page":"16313","DOI":"10.1021\/acs.jmedchem.2c01132","article-title":"Development of alkylated hydrazides as highly potent and selective class I histone deacetylase inhibitors with T cell modulatory properties","volume":"65","author":"Sun","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129810","article-title":"Replacement of the hydroxamic acid group in the selective HDAC8 inhibitor PCI-34051","volume":"108","author":"Long","year":"2024","journal-title":"Bioorg Med Chem Lett"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130312_bb0175","doi-asserted-by":"crossref","first-page":"9067","DOI":"10.1021\/acs.jmedchem.7b01444","article-title":"Controlling plasma stability of hydroxamic acids: a MedChem toolbox","volume":"60","author":"Hermant","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105695","article-title":"Histone deacetylase 2 selective inhibitors: a versatile therapeutic strategy as next generation drug target in cancer therapy","volume":"170","author":"Shetty","year":"2021","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmcl.2025.130312_bb0185","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ejmech.2017.08.069","article-title":"Targeting breast cancer stem cells by novel HDAC3-selective inhibitors","volume":"140","author":"Hsieh","year":"2017","journal-title":"Eur J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2025.130312_bb0190","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/leu.2008.9","article-title":"A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas","volume":"22","author":"Balasubramanian","year":"2008","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130312_bb0195","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/cmdc.201300414","article-title":"Design, synthesis, and biological activity of NCC149 derivatives as histone deacetylase 8-selective inhibitors","volume":"9","author":"Suzuki","year":"2014","journal-title":"ChemMedChem"},{"issue":"22","key":"10.1016\/j.bmcl.2025.130312_bb0200","doi-asserted-by":"crossref","first-page":"10000","DOI":"10.1021\/acs.jmedchem.8b01087","article-title":"Characterization of histone deacetylase 8 (HDAC8) selective inhibition reveals specific active site structural and functional determinants","volume":"61","author":"Marek","year":"2018","journal-title":"J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130312_bb0205","doi-asserted-by":"crossref","first-page":"10528","DOI":"10.1021\/acs.jmedchem.3c00644","article-title":"Discovery of HDAC6, HDAC8, and 6\/8 inhibitors and development of cell-based drug screening models for the treatment of TGF-\u0392-induced idiopathic pulmonary fibrosis","volume":"66","author":"Yu","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116571","article-title":"Advances in dual-targeting inhibitors of HDAC6 for cancer treatment","volume":"275","author":"Gu","year":"2024","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2025.130312_bb0215","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2004.04.012","article-title":"Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases","volume":"12","author":"Somoza","year":"2004","journal-title":"Structure"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130312_bb0220","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.3390\/ijms231710014","article-title":"A therapeutic perspective of HDAC8 in different diseases: An overview of selective inhibitors","volume":"23","author":"Fontana","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130312_bb0225","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1016\/j.bmcl.2011.01.134","article-title":"Discovery of histone deacetylase 8 selective inhibitors","volume":"21","author":"Tang","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"issue":"24","key":"10.1016\/j.bmcl.2025.130312_bb0230","doi-asserted-by":"crossref","first-page":"10188","DOI":"10.1021\/acs.jmedchem.7b01447","article-title":"Structure-based design and biological characterization of selective histone deacetylase 8 (HDAC8) inhibitors with anti-neuroblastoma activity","volume":"60","author":"Heimburg","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0235","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ejmech.2018.03.002","article-title":"Discovery of meta-sulfamoyl N-hydroxybenzamides as HDAC8 selective inhibitors","volume":"150","author":"Zhao","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130312_bb0240","doi-asserted-by":"crossref","first-page":"8634","DOI":"10.1021\/acs.jmedchem.0c01025","article-title":"Characterization of conformationally constrained benzanilide scaffolds for potent and selective HDAC8 targeting","volume":"63","author":"Hassan","year":"2020","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.bmcl.2025.130312_bb0245","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1021\/acsmedchemlett.7b00126","article-title":"Design, synthesis, and biological evaluation of Tetrahydroisoquinoline-based histone deacetylase 8 selective inhibitors","volume":"8","author":"Taha","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"10","key":"10.1016\/j.bmcl.2025.130312_bb0250","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/cmdc.201200300","article-title":"Synthesis and biological evaluation of ortho-aryl N-Hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors","volume":"7","author":"Huang","year":"2012","journal-title":"ChemMedChem"},{"issue":"5\u20136","key":"10.1016\/j.bmcl.2025.130312_bb0255","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1002\/jcb.29583","article-title":"Exploring the binding mechanism of HDAC8 selective inhibitors: lessons from the modification of cap group","volume":"121","author":"Zhang","year":"2020","journal-title":"J Cell Biochem"},{"issue":"14","key":"10.1016\/j.bmcl.2025.130312_bb0260","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/S0277-5387(00)00453-8","article-title":"Coordination modes of hydroxamic acids in copper(II), nickel(II) and zinc(II) mixed-ligand complexes in aqueous solution","volume":"19","author":"Farkas","year":"2000","journal-title":"Polyhedron"},{"issue":"6","key":"10.1016\/j.bmcl.2025.130312_bb0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/anie.197403761","article-title":"The chemistry of hydroxamic acids and N-Hydroxyimides","volume":"13","author":"Bauer","year":"1974","journal-title":"Angew Chem Int Ed"},{"issue":"17","key":"10.1016\/j.bmcl.2025.130312_bb0270","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.3390\/molecules26175151","article-title":"Non-Hydroxamate zinc-binding groups as warheads for histone deacetylases","volume":"26","author":"Fr\u00fchauf","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0275","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/10426507.2011.568025","article-title":"A facile oxidation of thiols to disulfides catalyzed by CoSalen","volume":"187","author":"Tan","year":"2011","journal-title":"Phosphorus Sulfur Silicon Relat Elem"},{"issue":"13","key":"10.1016\/j.bmcl.2025.130312_bb0280","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1016\/j.bmc.2013.04.036","article-title":"Structural basis for the design and synthesis of selective HDAC inhibitors","volume":"21","author":"Di Micco","year":"2013","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0285","doi-asserted-by":"crossref","first-page":"5543","DOI":"10.1021\/jm701079h","article-title":"Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity","volume":"50","author":"Moradei","year":"2007","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmcl.2025.130312_bb0290","article-title":"Balancing histone deacetylase (HDAC) inhibition and drug-likeness: biological and physicochemical evaluation of class I selective HDAC inhibitors","volume":"17","author":"Sch\u00e4ker-H\u00fcbner","year":"2022","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130312_bb0295","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1042\/BJ20111685","article-title":"CS055 (Chidamide\/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells","volume":"443","author":"Gong","year":"2012","journal-title":"Biochem J"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130312_bb0300","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1016\/j.bmc.2011.06.030","article-title":"Human HDAC isoform selectivity achieved via exploitation of the acetate release channel with structurally unique small molecule inhibitors","volume":"19","author":"Whitehead","year":"2011","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130312_bb0305","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1747-0285.2012.01382.x","article-title":"The chemical tuning of a weak zinc binding motif for histone deacetylase using electronic effects","volume":"80","author":"McCarren","year":"2012","journal-title":"Chem Biol Drug Des"},{"key":"10.1016\/j.bmcl.2025.130312_bb0310","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1021\/acs.jmedchem.0c00442","article-title":"Design of Hydrazide-Bearing HDACIs based on Panobinostat and their p53 and FLT3-ITD dependency in Antileukemia activity","volume":"63","author":"Li","year":"2020","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130312_bb0315","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/molecules23030566","article-title":"A novel class of Schistosoma mansoni histone deacetylase 8 (HDAC8) inhibitors identified by structure-based virtual screening and in vitro testing","volume":"23","author":"Simoben","year":"2018","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.bmcl.2025.130312_bb0320","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/cmdc.200900309","article-title":"Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors","volume":"4","author":"Galletti","year":"2009","journal-title":"ChemMedChem"},{"issue":"21","key":"10.1016\/j.bmcl.2025.130312_bb0325","doi-asserted-by":"crossref","first-page":"15067","DOI":"10.1021\/acs.joc.3c01520","article-title":"Anomeric answer to sulfenamide stability and \u0391-Nucleophilicity","volume":"88","author":"Wall","year":"2023","journal-title":"J Organic Chem"},{"issue":"23","key":"10.1016\/j.bmcl.2025.130312_bb0330","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/cmdc.201600528","article-title":"Potent and selective non-hydroxamate histone deacetylase 8 inhibitors","volume":"11","author":"Kleinschek","year":"2016","journal-title":"ChemMedChem"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130312_bb0335","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.bbagen.2019.01.001","article-title":"Covalent inhibition of histone deacetylase 8 by 3,4-dihydro-2H-pyrimido[1,2-c][1,3]benzothiazin-6-imine","volume":"1863","author":"Muth","year":"2019","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"1","key":"10.1016\/j.bmcl.2025.130312_bb0340","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem Funct"},{"issue":"2","key":"10.1016\/j.bmcl.2025.130312_bb0345","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1039\/D0MD00286K","article-title":"Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6","volume":"12","author":"Chan","year":"2020","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.bmcl.2025.130312_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106546","article-title":"Discovery of highly potent HDAC8 PROTACs with anti-tumor activity","volume":"136","author":"Zhao","year":"2023","journal-title":"Bioorg Chem"},{"issue":"15","key":"10.1016\/j.bmcl.2025.130312_bb0355","doi-asserted-by":"crossref","first-page":"6574","DOI":"10.1021\/acs.jmedchem.8b00050","article-title":"Design and synthesis of tubulin and histone deacetylase inhibitor based on Iso-Combretastatin A-4","volume":"61","author":"Lamaa","year":"2018","journal-title":"J Med Chem"},{"issue":"88","key":"10.1016\/j.bmcl.2025.130312_bb0360","doi-asserted-by":"crossref","first-page":"72373","DOI":"10.1039\/C5RA12606A","article-title":"Design of dual MMP-2\/HDAC-8 inhibitors by pharmacophore mapping, molecular docking, synthesis and biological activity","volume":"5","author":"Halder","year":"2015","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmcl.2025.130312_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112338","article-title":"Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6\/8 and bromodomain BRPF1","volume":"200","author":"Ghazy","year":"2020","journal-title":"Eur J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25002215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:19:05Z","timestamp":1776917945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25002215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":73,"alternative-id":["S0960894X25002215"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130312","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent progress in synthetic strategies to develop potent, HDAC8-selective, small-molecule inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130312","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"130312"}}